Asset Details
Do you wish to reserve the book?
Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma
Do you wish to request the book?
Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma
2021
Overview
Background
ZMYND8 (Zinc finger MYND (Myeloid, Nervy and DEAF-1)-type containing 8)
has been known to play an important role in tumor regulation in various types of cancer. However, the results of
ZMYND8
expression and their clinical significance in hepatocellular carcinoma (HCC) have not yet been published. In the present study, we investigate the expression of ZMYND8 protein and mRNA in HCC and elucidate its prognostic significance.
Methods
ZMYND8 protein and mRNA expression in 283 and 234 HCCs were investigated using immunohistochemistry and microarray gene expression profiling data. The relationships between ZMYND8 expression with clinicopathologic features and prognosis of HCC patients were evaluated. Furthermore, we performed the invasion, migration, apoptosis, soft agar formation assay and sphere formation assay in HCC cell lines, and evaluated tumorigenicity in a nude mouse model, after
ZMYND8
knockdown.
Results
Overexpression of ZMYND8 protein and mRNA was observed in 20.5% and 26.9% of HCC cases, respectively. High ZMYND8 expression showed significant correlations with microvascular invasion, high Edmondson grade, advanced American Joint Committee on Cancer, and increased alpha-fetoprotein level.
ZMYND8
mRNA overexpression was an independent prognostic factor for predicting early recurrence as well as short recurrence-free survival (RFS). Downregulation of
ZMYND8
reduced migration and invasion of HCC cells, and promoted apoptosis of HCC cells in an in vitro model. In a xenograft nude mouse model, knockdown of
ZMYND8
significantly reduced tumor growth.
Conclusion
ZMYND8
mRNA overexpression could be a prognostic marker of shorter RFS in HCC patients after curative resection. ZMYND8 might play an important role in the proliferation and progression of HCC and could be a promising candidate for targeted therapy.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Animals
/ Biomarkers, Tumor - metabolism
/ Carcinoma, Hepatocellular - metabolism
/ Carcinoma, Hepatocellular - pathology
/ Cell Proliferation - physiology
/ Female
/ Humans
/ Liver Neoplasms - metabolism
/ Male
/ Medicine
/ Mice
/ Oncology
/ Original Article – Cancer Research
/ Patients
/ Proteins
/ Tumor Suppressor Proteins - metabolism
/ Tumors
